Statins and breast cancer: Future directions in chemoprevention

Research output: Contribution to journalArticle

Abstract

Given the high incidence, morbidity and mortality associated with breast cancer, developing effective chemopreventive strategies is crucial. Clinicians must carefully identify both populations at risk who would benefit from chemoprevention, and interventions that are effective and safe. Tamoxifen and raloxifene, the 2 agents approved for breast cancer chemoprevention, and third generation aromatase inhibitors reduce only the incidence of hormone receptor-positive tumors. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) inhibitors, or statins, are well tolerated and approved for prevention of cardiovascular disease. In preclinical breast cancer models, statins carry potent anti-neoplastic activity. Results from epidemiological and clinical studies, however, are conflicting and have not identified a strong relationship between statin use and reduced breast cancer incidence. These studies have several limitations and were not designed to detect modest effects in high-risk populations. Additional focused epidemiological and translational studies in high-risk populations are needed to justify and guide definitive large prospective trials.

Original languageEnglish (US)
Pages (from-to)161-169
Number of pages9
JournalCurrent Breast Cancer Reports
Volume5
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chemoprevention
Breast Neoplasms
Epidemiologic Studies
Incidence
Aromatase Inhibitors
Tamoxifen
Population
Oxidoreductases
Cardiovascular Diseases
Hormones
Morbidity
Mortality
Direction compound
Neoplasms

Keywords

  • Biomarkers
  • Breast cancer risk
  • Cancer recurrence
  • Cancer review
  • Chemoprevention
  • High-risk populations
  • HMG-CoAR inhibitors
  • Statins

ASJC Scopus subject areas

  • Oncology

Cite this

Statins and breast cancer : Future directions in chemoprevention. / Santa-Maria, Cesar; Stearns, Vered.

In: Current Breast Cancer Reports, Vol. 5, No. 3, 09.2013, p. 161-169.

Research output: Contribution to journalArticle

@article{90569a7c5e1e47b083ba30029a60589d,
title = "Statins and breast cancer: Future directions in chemoprevention",
abstract = "Given the high incidence, morbidity and mortality associated with breast cancer, developing effective chemopreventive strategies is crucial. Clinicians must carefully identify both populations at risk who would benefit from chemoprevention, and interventions that are effective and safe. Tamoxifen and raloxifene, the 2 agents approved for breast cancer chemoprevention, and third generation aromatase inhibitors reduce only the incidence of hormone receptor-positive tumors. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) inhibitors, or statins, are well tolerated and approved for prevention of cardiovascular disease. In preclinical breast cancer models, statins carry potent anti-neoplastic activity. Results from epidemiological and clinical studies, however, are conflicting and have not identified a strong relationship between statin use and reduced breast cancer incidence. These studies have several limitations and were not designed to detect modest effects in high-risk populations. Additional focused epidemiological and translational studies in high-risk populations are needed to justify and guide definitive large prospective trials.",
keywords = "Biomarkers, Breast cancer risk, Cancer recurrence, Cancer review, Chemoprevention, High-risk populations, HMG-CoAR inhibitors, Statins",
author = "Cesar Santa-Maria and Vered Stearns",
year = "2013",
month = "9",
doi = "10.1007/s12609-013-0119-7",
language = "English (US)",
volume = "5",
pages = "161--169",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Statins and breast cancer

T2 - Future directions in chemoprevention

AU - Santa-Maria, Cesar

AU - Stearns, Vered

PY - 2013/9

Y1 - 2013/9

N2 - Given the high incidence, morbidity and mortality associated with breast cancer, developing effective chemopreventive strategies is crucial. Clinicians must carefully identify both populations at risk who would benefit from chemoprevention, and interventions that are effective and safe. Tamoxifen and raloxifene, the 2 agents approved for breast cancer chemoprevention, and third generation aromatase inhibitors reduce only the incidence of hormone receptor-positive tumors. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) inhibitors, or statins, are well tolerated and approved for prevention of cardiovascular disease. In preclinical breast cancer models, statins carry potent anti-neoplastic activity. Results from epidemiological and clinical studies, however, are conflicting and have not identified a strong relationship between statin use and reduced breast cancer incidence. These studies have several limitations and were not designed to detect modest effects in high-risk populations. Additional focused epidemiological and translational studies in high-risk populations are needed to justify and guide definitive large prospective trials.

AB - Given the high incidence, morbidity and mortality associated with breast cancer, developing effective chemopreventive strategies is crucial. Clinicians must carefully identify both populations at risk who would benefit from chemoprevention, and interventions that are effective and safe. Tamoxifen and raloxifene, the 2 agents approved for breast cancer chemoprevention, and third generation aromatase inhibitors reduce only the incidence of hormone receptor-positive tumors. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) inhibitors, or statins, are well tolerated and approved for prevention of cardiovascular disease. In preclinical breast cancer models, statins carry potent anti-neoplastic activity. Results from epidemiological and clinical studies, however, are conflicting and have not identified a strong relationship between statin use and reduced breast cancer incidence. These studies have several limitations and were not designed to detect modest effects in high-risk populations. Additional focused epidemiological and translational studies in high-risk populations are needed to justify and guide definitive large prospective trials.

KW - Biomarkers

KW - Breast cancer risk

KW - Cancer recurrence

KW - Cancer review

KW - Chemoprevention

KW - High-risk populations

KW - HMG-CoAR inhibitors

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84884356364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884356364&partnerID=8YFLogxK

U2 - 10.1007/s12609-013-0119-7

DO - 10.1007/s12609-013-0119-7

M3 - Article

C2 - 23997864

AN - SCOPUS:84884356364

VL - 5

SP - 161

EP - 169

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 3

ER -